Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
NCT ID: NCT05701007
Last Updated: 2024-04-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1 participants
OBSERVATIONAL
2023-02-13
2024-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* What are the demographic and clinical characteristics of metastatic prostate cancer patients?
* How are metastatic prostate cancer patients currently treated and how effective are these treatments?
* How does the development of castration-resistance affect patient outcomes?
* What is the economic burden of metastatic prostate cancer?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Retrospective Study to Describe the Real-world Treatment Patterns and Associated Clinical Outcomes in Patients With Metastatic Castration-resistant Prostates Cancer
NCT04801186
A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)
NCT07086651
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
NCT05352178
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
NCT05212857
A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).
NCT06551324
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients diagnosed with metastatic castration sensitive prostate cancer (mCSPC)
degarelix
mCSPC
goserelin
mCSPC
leuprorelin
mCSPC
triptorelin
mCSPC
Patients diagnosed with metastatic castration resistant prostate cancer (mCRPC)
abiraterone
mCRPC
enzalutamide
mCRPC
docetaxel
mCRPC
apalutamide
mCRPC
cabazitaxel
mCRPC
Radium-223
mCRPC
Lutetium-177
mCRPC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
abiraterone
mCRPC
enzalutamide
mCRPC
docetaxel
mCRPC
apalutamide
mCRPC
cabazitaxel
mCRPC
Radium-223
mCRPC
Lutetium-177
mCRPC
degarelix
mCSPC
goserelin
mCSPC
leuprorelin
mCSPC
triptorelin
mCSPC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC)
* Detection of metastatic prostate cancer
Exclusion Criteria
* Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PrCa-RWD
Identifier Type: OTHER
Identifier Source: secondary_id
C3441057
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.